We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

MINDRAY In-Vitro Diagnostics

  Gold As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Diagnostic Value of Hematology Parameters Investigated for Hemophagocytic Lymphohistiocytosis

By LabMedica International staff writers
Posted on 04 Aug 2021
Print article
Image: Mindray Double Chamber BC-5130 Auto Hematology Analyzer (Photo courtesy of Mindray)
Image: Mindray Double Chamber BC-5130 Auto Hematology Analyzer (Photo courtesy of Mindray)
Hemophagocytic lymphohistiocytosis (HLH) is a severe rare syndrome characterized by pathologic immune activation and hyperinflammation with harmful effects on multiple organs. The clinical presentations of HLH may include fever, cytopenias, splenomegaly, and hyperferritinemia, none of which is specific for this rare though life-threatening condition.

HLH shares similarities with other inflammatory states, for example, sepsis, and the high inflammatory response present in both states of HLH and sepsis provides overlapping clinical features, including fever and worsening clinical status. The differential diagnosis of HLH and sepsis is critically important because the life-saving aggressive immunosuppressive treatment, required in the effective HLH therapy, is absent in sepsis guidelines.

Clinical Laboratorians at the Zhejiang University School of Medicine (Hangzhou, China) conducted a retrospective study, involving 71 HLH patients, 105 sepsis patients, and 88 normal controls from January 2018 to December 2019. Children were classified as HLH if they meet at least five of the eight criteria of the International Histiocyte Society (2004-HLH criteria).

Peripheral blood samples were collected from all the participants for the first time. After treatment, peripheral blood samples from HLH patients were also collected. Complete blood counts were analyzed by hematology analyzer BC-5310 (Mindray, Nanshan, China). Red blood cell distribution width (RDW) and platelet distribution width (PDW) levels were collected from patients’ complete blood count, and RDW to platelet count ratio (RPR) was calculated as the ratio of RDW and platelet counts.

The scientists reported that nearly all the patients demonstrated fever and splenomegaly were present in more than 90% of the patients (fever: 70/71, 98.59%; splenomegaly: 68/71, 95.77%). Other clinical and laboratory tests included anemia (44/71, 61.97%), neutropenia (38/71, 53.52%), thrombocytopenia (33/71, 46.48%), hypofibrinogenemia (44/71, 61.97%), hypertriglyceridemia (28/71, 39.44%), hyperferritinemia (49/71, 69.01%), impaired NK-cell activity (47/71, 66.20%), and hemophagocytosis (20/24, 83.33%).

RDW, PDW, and RPR levels of the HLH patients were significantly higher than those of sepsis and normal controls. In ROC curve analysis of the RDW, PDW, and RPR for diagnosis of HLH, the area under the curve (AUC) reached to 0.78, 0.784, and 0.927, respectively. When using the criteria of RDW >13.75, PDW >13.30, and RPR >0.08, the sensitivity was 76.06%, 67.61%, and 84.51%, while the specificity was 68.57%, 85.71%, and 87.62%, respectively. After treatment of HLH patients, PDW and RPR were significantly reduced.

The authors concluded that their study indicated that cost-effective and easily calculated hematological parameters RDW, PDW, and RPR are novel indicators for differential diagnosis of HLH and sepsis. PDW and RPR could be additional biomarkers for monitoring therapeutic effects of HLH. The study was published on July 17, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:

Zhejiang University School of Medicine
Mindray


New
Gold Supplier
HAI Assay Quality Control
Amplichek II
New
Zika, Chikungunya and Dengue Rapid Test
DPP ZCD IgM/IgG System
New
Legionella Pneumophila Assay
C4Legio LFA
New
Gold Supplier
Body Fluid Application
CellaVision Body Fluid Application

Print article

Channels

Molecular Diagnostics

view channel
Image: New chip could make treating metastatic cancer easier and faster (Photo courtesy of Georgia Institute of Technology)

Simple Blood Test Detection Method Could Revolutionize Cancer Treatment

Cancer spreads via circulating tumor cells (CTCs) that travel through the blood to other organs, and they are nearly impossible to track. When a tumor starts metastasizing, it sheds its cell into the blood.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.